Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4916 SAD and MAD in Healthy Volunteers
NCT06951880Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, single-blind trial comparing AZD4916 with Placebo (2 arms). Primary endpoint: Number of participants with adverse events at 44 days. Started Jul 2026; status: recruiting.
02
Drugs
AZD4916
Beyond the preview
Go deeper on NCT06951880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06951880.